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Introduction
HSCT has long been established as an indispensable life-saving treatment, in
particular against acute hematologic malignancies.1 Despite the significant
progress made in the last ten years, transplantation related mortality and graft-ver-
sus-host disease (GvHD) continue to substantially constrain the curative potential
of HSCT, even in an HLA-matched context, underscoring the need to explore the
role of other immune system-related genetic factors in HSCT.2 In this respect, a
rather limited number of studies sought to investigate the effect of HLA-E on
HSCT outcome, considering  the significant immunomodulatory features of this
molecule implicated in both innate and adaptive immunity.3,4 HLA-E, a member of
The immunomodulatory role of human leukocyte antigen (HLA)-Ein hematopoietic stem cell transplantation (HSCT) has not beenextensively investigated. To this end, we genotyped 509 10/10
HLA unrelated transplant pairs for HLA-E, in order to study the effect of
HLA-E as a natural killer (NK)-alloreactivity mediator on HSCT outcome
in an acute leukemia (AL) setting. Overall survival (OS), disease free sur-
vival (DFS), relapse incidence (RI) and non-relapse mortality (NRM) were
set as endpoints. Analysis of our data revealed a significant correlation
between HLA-E mismatch and improved HSCT outcome, as shown by
both univariate (53% vs. 38%, P=0.002, 5-year OS) and multivariate
(hazard ratio (HR)=0.63, confidence interval (CI) 95%=0.48-0.83,
P=0.001) analyses. Further subgroup analysis demonstrated that the pos-
itive effect of HLA-E mismatch was significant and pronounced in
advanced disease patients (n=120) (5-year OS: 50% vs. 18%, P=0.005;
HR=0.40, CI 95%=0.22-0.72, P=0.002; results from univariate and mul-
tivariate analyses, respectively). The study herein is the first to report an
association between HLA-E incompatibility and improved post–trans-
plant prognosis in AL patients who have undergone matched unrelated
HSCT. Combined NK and T cell HLA-E-mediated mechanisms may
account for the better outcomes observed. Notwithstanding the necessi-
ty for in vitro and confirmational studies, our findings highlight the clini-
cal relevance of HLA-E matching and strongly support prospective HLA-
E screening upon donor selection for matched AL unrelated HSCTs.
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ABSTRACT
the non-classical HLA-Ib family, is ubiquitously
expressed on all nucleated cells, but at lower expression
levels than the classical HLA-class I molecules.5 It is rather
nonpolymorphic, with basically two functional forms of
the protein found worldwide at similar prevalence rates,6
shares an almost identical structural pattern with its clas-
sical HLA-class I counterpart and is viewed as a surrogate
marker for HLA-class I expression, as the leader
sequences of the latter constitute its main peptide reser-
voir.7 Even though this prominent allelic variation derives
from a single arginine to a glycine amino acid substitution
at position 107 of the heavy chain α2 domain (HLA-
E*01:01 and HLA-E*01:03, respectively), the codominance
of the two alleles in conjunction with their significantly
different expression levels on cell surfaces imply function-
al differences which are yet to be fully understood.8-10 As
a basic ligand to CD94/NKG2A,11 a robust inhibitory
receptor found on the surface of NK cells and NK-like
cytotoxic T lymphocytes (CTLs), the principal role of
HLA-E is considered to be the protection of normal cells
from aberrant NK killing. However, continuously arising
data highlight that HLA-E may hold a much more multi-
faceted role in immune response by presenting “uncon-
ventional” peptides under stress conditions12,13 and by
interacting with HLA-E-restricted CD8+ CTLs and regula-
tory T cells (Tregs) via their αβ T-cell receptors (TCRs) as
well as with the activating CD94/NKG2C receptor on the
surface of NK-cells and NK-like CTLs.14,15 Despite the evi-
dent role of HLA-E in immune response, no definite con-
clusions can be drawn from studies published thus far
aiming to establish an association between HLA-E and
HSCT outcome.16-24 The aim of the present study was to
explore not only the role of HLA-E genotype but, prima-
rily, the effect of HLA-E patient-donor compatibility on
HSCT outcome, as the weak linkage disequilibrium
between HLA-E and its classical HLA counterparts leads
to a rather high rate of HLA-E mismatches among  HLA-
A, -B, -C, -DRB1, and HLA-DQB1 allele-matched HSCT
pairs.17,25 HLA-E as an NK-alloreactivity mediator is
expected to have a more prominent role in an AL context
where the graft-versus-leukemia effect (GvL) is of utmost
relevance. Hence, we applied a study design including
only adult AL patients who had undergone a 10/10 HLA-
matched unrelated HSCT in order to evaluate the role of
patient/donor HLA-E genotypes as well as of HLA-E
matching status in HSCT outcome.  
Methods
Patients
509 adult patients diagnosed with AL, receiving their first allo-
geneic HSCT between 2002 and 2009 were included in the study.
All patients were transplanted with 10/10 allele level HLA-A, -B, -
C, -DRB1, -DQB1-matched grafts, which were either bone mar-
row (BM) or peripheral blood stem cells (PBSCs). We included
only those patients diagnosed with acute myeloid leukemia
(AML), acute lymphoblastic leukemia (ALL) as well as undefined
AL (undifferentiated, biphenotypic or secondary acute). Disease
stages were assigned according to a previous report published by
the European Society for Blood and Marrow Transplantation
(EBMT) study group.26 Early disease stage included AML, AL, and
ALL transplanted in first complete remission, intermediate disease
stage was defined as AML and ALL in second complete remission
or first relapse as well as AL transplanted in second complete
remission. All other disease phases of AML, ALL and AL were
characterized as advanced stage. All patients were treated with
myeloablative (Mab) or reduced intensity conditioning (RIC).27,28
Recipient and donor consents for HLA typing and for the analysis
of clinical data were obtained in accordance with the Declaration
of Helsinki upon initiation of donor search and registration in the
EBMT database, respectively. All clinical data were initially
recorded in the EBMT ProMISE database and were subsequently
provided to us by the German Registry for Stem Cell
Transplantation (DRST), which is responsible for the clinical data
management of the German patients’ subset. The study was
approved by the ethical review board of the University of Ulm
(project number: 263/09).
HLA-typing
All patients and their respective donors were genotyped at high
resolution level for the HLA-loci A, B, C, DRB1 and DQB1. 
HLA-DPB1 genotyping was performed retrospectively for all
study subjects using stored DNA material. Permissiveness of
DPB1-mismatches was assessed according to the TCE (T-cell epi-
tope) algorithm.29 Additional testing for relevant non-expressed
alleles was performed according to the National Marrow Donor
Program confirmatory typing requirements.30 
Killer Cell Immunoglobulin-Like Receptors (KIR) typing
KIR-typing was performed using the commercially available
“KIR Genotyping SSP Kit” from Life Technologies (Carlsbad, CA,
USA). Donor KIR AA and Bx haplotypes were assigned as previ-
ously described.31
HLA-E typing
All 509 patient-donor pairs were HLA-E high resolution geno-
typed. HLA-E specific primers were designed for complete Exon 2
and 3 sequencing analysis, allowing precise assignment of all
known allelic variants.  Allelic assignment was based on sequence
data retrieved from the  immunogenetics (IMGT)/HLA database. 
Statistical analysis
The cumulative estimates for the univariate analysis OS and
DFS were obtained using the Kaplan-Meier method. For multivari-
ate analyses Cox regression models were implemented.
Competing risk analysis was used for the univariate analyses of
NRM, RI and chronic (c)GvHD incidence, while competing risk
regression models for stratified data were used for multivariate
analyses. Acute (a)GvHD and severe infection incidence as well as
prevalence of other causes of death are reported descriptively.
Center effects were adjusted using a γ frailty term.32
Statistical models covered covariates in accordance with the
previously published recommendations of the EBMT study
group.28,33 In addition to these, patient and donor cytomegalovirus
(CMV) serostatus, treatment with anti-thymocyte globulin (ATG),
Karnofsky performance score (KPS) at time of transplantation,
donor KIR haplotype (AA/Bx),31 patient C1/C2 KIR ligand status
as well as HLA-DPB1 compatibility (based on T-cell epitope algo-
rithm)29 were also evaluated. Missing data were treated as sepa-
rate categories in multivariate analyses.26 A stepwise backward
exclusion procedure was used for model selection.26,28 Statistical
significance was set to a P-value≤0.05. All statistical analyses were
performed using the open source program for statistical comput-
ing “R”, version 3.1.0. 
More section data available in Online Supplementary Material.
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Table 1. Cohort characteristics.
Category Study cohort n(%) HLA-E-matched n(%) HLA-E-mismatched n(%) P
Number of patients 509 320 189
Number of transplantation centers 21 20 (95.2) 20 (95.2) 0.61
Age category
18-29 97 (19.0) 62 (19.4) 35 (18.5)
30-39 71 (14.0) 32 (10.0) 39 (20.6)
40-49 89 (17.5) 62 (19.4) 27 (14.3) 0.24
50-59 129 (25.3) 82 (25.6) 47 (24.9)
60-69 108 (21.2) 75 (23.4) 33 (17.5)
70-79 15 (3.0) 7 (2.2) 8 (4.2)
Diagnosis
AML 313 (61.5) 196 (61.2) 117 (61.9) 0.89
ALL 132 (25.9) 85 (26.6) 47 (24.9)
AL 64 (12.6) 39 (12.2) 25 (13.2)
Disease stage
Early 237 (46.5) 147 (45.9) 90 (47.6)
Intermediate 152 (29.9) 92 (28.8) 60 (31.7) 0.46
Advanced 120 (23.6) 81 (25.3) 39 (20.6)
Conditioning regimen
Myeloablative 345 (67.8) 215 (67.2) 130 (68.8) 0.78
Reduced intensity 164 (32.2) 105 (32.8) 59 (31.2)
Karnofsky performance score*
KPS < 90 98 (30.6) 66 (32.0) 32 (28.1) 0.50
Missing data 189 (37.1) 114 (35.6) 75 (39.7)
Stem cell source
BM 32 (6.3) 18 (5.6) 14 (7.4) 0.54
PBSC 477 (93.7) 302 (94.4) 175 (92.6)
ATG Treatment*
Yes 252 (63.2) 157 (61.3) 95 (66.4) 0.31
No 147 (37.8) 99 (38.7) 48 (33.6)
Missing data 110 (21.6) 64 (20.0) 46 (24.3)
Patient-Donor CMV serostatus combination*
neg neg 126 (31.6) 81 (32.1) 45 (30.6)
neg pos 45 (11.3) 31 (12.3) 14 (9.5)
pos neg 102 (25.5) 61 (24.2) 41(27.9) 0.86
pos pos 126 (31.6) 79 (31.4) 47 (32.0)
Missing data 110 (21.6) 68 (21.2) 42 (22.2)
Donor KIR Haplotype*
Haplotype AA 158 (31.3) 95 (30.0) 63 (33.7)
Haplotype Bx 346 (68.7) 222 (70.0) 124 (66.3) 0.68
Missing data 5 (0.98) 3 (0.94) 2 (1.0)
Patient C1/C2 KIR ligands
C1 positive 443 (87.0) 277 (86.6) 166 (87.8) 0.86
C1 negative 66 (13.0) 43 (13.4) 23 (12.2)
HLA-DPB1 TCE mismatch*
Permissive 326 (64.3) 208 (65.2) 118 (62.8)
HvG non-permissive 86 (17.0) 59 (18.5) 27 (14.4)
GvH non-permissive 95 (18.7) 52 (16.3) 43 (22.8) 0.13
Missing data 2 (0.4) 1 (0.3) 1 (0.5)
continued on next page
Results
Patient characteristics
Patient cohort characteristics regarding HSCT outcome
predictors and in relation to HLA-E matching status
between patient and donor are summarized in Table 1. For
the 509 patients included in the study, median post-trans-
plant follow-up time was almost 5 years (4.97 years),
while median patient age was 49 years (range: 18-74
years). Interestingly, 37.1% of the cases were HLA-E-mis-
matched, and as the P-values in Table 1 suggest, there was
no biased distribution of HLA-E-matched and mis-
matched cases with regard to other parameters predictive
for the outcome of HSCT which we evaluated.    
HLA-E genotyping results
A summary of the HLA-E genotyping results is dis-
played in Table 2. The HLA-E allele frequencies found
were in accordance with those previously reported for
Caucasian populations,6,17,25 confirming the codominant
prevalence of the two basic allelic forms of HLA-E. No dif-
ferences were identified regarding the distribution of the
HLA-E allelic variants between patients and donors. 
HLA-E*01:03, 01:03 patient genotype is not 
associated with better HSCT outcome
Our results do not confirm the findings of previously
published studies regarding the positive impact of patient
HLA-E*01:03, 01:03 genotype on HSCT outcome. On the
contrary, HLA-E*01:03, 01:03 patients in our cohort had
worse OS, DFS and NRM rates compared to the patients
carrying the two other genotypes as shown in the multi-
variate analysis (OS: HR=1.45, CI 95%=1.00-2.10, P=0.05;
DFS: HR=1.47, CI 95%=1.04-2.07, P=0.03; NRM:
HR=1.74, CI 95%=1.09-2.78, P=0.02). Of note, this find-
ing did not reach statistical significance in any of the uni-
variate models (data not shown). 
HLA-E incompatibility significantly improves OS, DFS
and NRM
Analysis of OS, DFS and NRM with respect to HLA-E
matching status between patients and donors revealed a
significant favorable effect of HLA-E mismatch on these
endpoints. As shown in Figure 1, patients transplanted
with HLA-E-mismatched donors exhibit a significantly
improved 5-year OS (53% vs. 38%, P=0.002), 5-year DFS
(45% vs. 32%, P=0.007) and a significantly lower 5-year
NRM (26% vs. 37%, P=0.006) when compared to cases
receiving an HLA-E compatible graft. Multivariate analy-
ses confirmed the above findings as the beneficial effect of
HLA-E mismatch was statistically significant for all of the
above HSCT outcome endpoints (OS: HR=0.63, CI
95%=0.48-0.83, P=0.001; DFS: HR=0.71, CI 95%=0.55-
0.92, P=0.008; NRM: HR=0.63, CI 95%=0.43-0.91,
P=0.015). Since better OS appeared to stem from lower
NRM rates in the HLA-E-mismatched patient subgroup,
we separately analyzed the prevalence rates of aGvHD
and severe infection along with an overall cause of death
analysis. Although Grade III-IV aGvHD rates were similar
in the two groups (~10%), the death rate of 9% from
GvHD in the HLA-E-matched group was substantially
higher than the 5.8% found among HLA-E-mismatched
patients. Furthermore, severe infection was reported in
17.2% of HLA-E-matched patients vs. 9.5% of HLA-E-
mismatched patients. Accordingly, infection-related mor-
tality was higher in the HLA-E-matched group (10.9% vs.
7.9%).  
It should be noted that data on both aGvHD and
cGvHD were incomplete for 9% (46/509) and 43%
(217/509) of cases, respectively. No cause of death data
were available for 2.1% of patients (11/509). With regard
to cGvHD, presuming that missing values were most like-
ly randomly distributed among HLA-E-matched and mis-
matched cases within our cohort, we decided to include
this parameter in the statistical analysis. The analysis of
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Recipient-donor sex match
Male-male 228 (44.8) 143 (44.7) 85 (45.0)
Male-female 46 (9.0) 26 (8.1) 20 (10.6)
Female-male 168 (33.0) 108 (33.8) 60 (31.7) 0.80
Female-female 67 (13.2) 43 (13.4) 24 (12.7)
Year of transplantation
2002-2005 127 (25.0) 77 (24.0) 50 (26.5) 0.62
2006-2009 382 (75.0) 243 (76.0) 139 (73.5)
*In compliance with the EBMT statistical guidelines, percentages for variables with missing data are presented with reference to the known data cases. AML: acute myeloid
leukemia; ALL: acute lymphoblastic leukemia; AL: acute leukemia not specified as AML or ALL (undifferentiated, biphenotypic or secondary acute); KPS: Karnofsky perform-
ance score; BM: bone marrow; PBSC: peripheral blood stem cells; ATG: anti-thymocyte globulin; CMV: cytomegalovirus;  pos: positive; neg: negative. KIR: killer cell immunoglob-
ulin-like receptor; HLA: human leukocyte antigen; TCE: T-cell epitope; HvG: Host vs. Graft; GvH: Graft vs. Host.
continued in the previous page
Table 2. Human leukocyte antigen (HLA)-E genotyping results.
HLA-E allele frequencies (n,%) HLA-E genotypes (n,%)
HLA-E* 01:01 01:03 01:07 01:01 01:01, 01:03 01:03 01:01, 01:07
Patients 567 (55.7) 451 (44.3) - 157 (30.8) 253 (49.7) 99 (19.5) -
Donors 572 (56.0) 445 (43.8) 1 (0.2) 151 (29.7) 269 (52.8) 88 (17.3) 1 (0.2)
the cumulative probability of cGVHD revealed a tendency
toward association between HLA-E mismatch and less
cGvHD. However, given the admittedly high number of
missing data, these results should be interpreted with cau-
tion. 
All results for both univariate and multivariate analyses
are summarized in Table 3. After stepwise backward
exclusion procedure used for model selection, patient age,
disease stage, diagnosis, CMV serostatus compatibility,
ATG treatment and patient HLA-E haplotype were inte-
grated as significant clinical predictors in our multivariate
analyses. 
Advanced disease acute leukemia patients benefit the
most from HLA-E-mismatched unrelated 10/10 HLA
matched HSCT
Exploratory controls for potential interactions between
HLA-E matching status and other clinical predictors
revealed an association between the “HLA-E mismatch
effect” and advanced disease stage. For this reason we
extended our analysis by dividing patients into an
advanced (n=120) and a non-advanced disease (n=389)
group, with the latter including patients in early or inter-
mediate disease stage. Both univariate and multivariate
analyses for OS, DFS and NRM revealed a much stronger
effect of HLA-E mismatch in the advanced disease group
compared to the early/intermediate stage patients. 
The 5-year survival rates were markedly improved in
advanced disease patients who received HLA-E disparate
grafts (OS: 50% vs. 18%, P=0.005; DFS: 40% vs. 12%,
P=0.002), as likewise depicted by the Kaplan-Meier curves
in Figure 2. NRM was also notably lower among these
patients (32% vs. 55%, P=0.038, Figure 2). Multivariate
analyses confirmed the above findings for all three end-
points in advanced disease patients (OS: HR=0.40, CI
95%=0.22-0.72, P=0.002; DFS: HR=0.42, CI 95%=0.25-
0.72, P=0.001; NRM: HR=0.44, CI 95%=0.20-0.95,
P=0.036). Additionally, HLA-E mismatch in advanced dis-
ease patients was associated with markedly higher rates
of none or mild (grade 0-I) aGvHD (66.7% vs. 56.8%) and
lower rates of grade II-IV aGvHD (7.7% vs. 12.3%).
Moreover, 14.8% of HLA-E-matched patients died due to
severe GvHD compared to only 2.6% of HLA-E-mis-
matched cases. No significant differences were observed
on account of severe infection prevalence between the
two groups (21.0% of HLA-E-matched vs. 17.9% of HLA-
E-mismatched cases). Interestingly, infection-related mor-
tality was higher in the HLA-E-mismatched group (17.9%
vs. 12.3%). Possible subjectivity involved in the reporting
of only one cause of death in the case of concomitant fatal
conditions may account for this discordance. It should be
underscored that no aGvHD data were available in 17.5%
(21/120) of cases, while cause of death data were incom-
plete for 2.5% (3/120) of advanced disease patients. The
effect of HLA-E mismatch in non-advanced disease
patients, albeit noticeable, did not reach statistical signifi-
cance for any of the endpoints in either univariate or mul-
tivariate analyses. No significant differences were identi-
fied in this subset of patients with respect to aGvHD rates
and GvHD-related death. However, there was a marked
difference observed regarding severe infection prevalence
with 15.9% in HLA-E-matched cases vs. 7.3% in HLA-E-
mismatched ones, likewise regarding infection-related
mortality rates (10.5% vs. 5.3% in HLA-E-matched and
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Table 3. Univariate and multivariate analyses as to the effect of human leukocyte antigen (HLA)-E mismatch on HSCT outcome.
Endpoints Univariate Analysis Multivariate Analysis 
Overall Survival HLA-E-matched HLA-E-mismatched P HR CI 95% P
1 year 0.59(0.53-0.65) 0.67(0.61-0.75)
3 year 0.42(0.36-0.49) 0.57(0.50-0.65) 0.002 0.63 0.48-0.83 0.001
5 year 0.38(0.32-0.44) 0.53(0.46-0.62)
Disease free survival
1 year 0.51(0.46-0.58) 0.59(0.52-0.66) 0.007 0.71 0.55-0.92 0.008
3 year 0.36(0.31-0.43) 0.51(0.44-0.59)
5 year 0.32(0.27-0.39) 0.45(0.38-0.53)
Non-relapse mortality
1 year 0.27(0.22-0.32) 0.19(0.14-0.26) 0.006 0.63 0.43-0.91 0.015
3 year 0.36(0.30-0.41) 0.22(0.16-0.29)
5 year 0.37(0.31-0.43) 0.26(0.19-0.33)
Relapse incidence
1 year 0.25(0.20-0.31) 0.25(0.19-0.32) 0.84 1.02 0.73-1.43 0.90
3 year 0.32(0.27-0.38) 0.31(0.24-0.38)
5 year 0.35(0.29-0.41) 0.34(0.26-0.41)
cGvHD incidence
6 months 0.34(0.27-0.42) 0.24(0.17-0.32) 0.102 0.70 0.47-1.04 0.074
12 months 0.39(0.31-0.46) 0.28(0.21-0.37)
24 months 0.39(0.32-0.47) 0.32(0.24-0.40)
Number of patients included in the analyses, n=509. Omitted observations due to missing data for overall survival (OS)=6, disease free survival (DFS)=4, non-relapse mortality=6,
relapse incidence= 20 and cGvHD incidence=217. Statistical significance is marked in italics. Hazard ratio (HR) values for survival endpoints (Overall survival and Disease free
survival) refer to the risk of death and/or relapse as measured in the analyses for these endpoints. cGvHD: chronic graft-versus-host disease.
mismatched cases, respectively). Cause of death data
were missing for 2% (8/389) of early/intermediate disease
patients. All results for both univariate and multivariate
analyses and for both patient subgroups are listed in
Tables 4 and 5, respectively. 
HLA-E mismatch has no effect on relapse incidence
rates
No differences in RI were observed with respect to
HLA-E matching status. Moreover, advanced as well as
non-advanced disease patients exhibited similar relapse
rates regardless of HLA-E matching status to their donor.
The results for RI are summarized in Tables 3-5.
Discussion
The immunomodulatory role of HLA-E and its implica-
tion in both innate and adaptive immunity has long been
investigated and established.4 Its impact, however, on
HSCT remains markedly elusive, as there are only a rela-
tively few number of studies with small and heteroge-
neous cohorts to be found in the literature;3 most of which
have aimed at establishing a correlation between certain
patient HLA-E genotypes and HSCT outcome. The study
herein is, to our knowledge, the first to report a favorable
effect of HLA-E incompatibility in an AL-matched unrelat-
ed HSCT setting. Our data suggest significantly improved
C. Tsamadou et al.
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Figure 1. Hematopoietic stem cell transplantation outcome with respect to
human leukocyte antigen (HLA)-E matching status in acute leukemia patients,
n=509. (A) Overall survival (P=0.002); (B) Disease free survival (P=0.007) and
(C) Non-relapse mortality (P=0.006) curves, respectively, of patients transplant-
ed with HLA-E-matched donors (black line) versus patients transplanted with
HLA-E-mismatched donors (red line).
Figure 2. Hematopoietic stem cell transplantation outcome with respect to
human leukocyte antigen (HLA)-E matching status in advanced disease
patients, n=120. (A) Overall survival (P=0.005); (B) Disease free survival,
(P=0.002) and (C) Non-relapse mortality (P=0.038) curves, respectively, of
patients transplanted with HLA-E-matched donors (black line) versus patients







overall and disease free survival rates as well as lower
NRM in adult AL patients transplanted with 10/10 HLA-
matched unrelated donors when grafts received were
HLA-E disparate. No effect was found in relation to
relapse incidence. Other confounding factors putatively
responsible for this observation were excluded, as HLA-E-
matched and mismatched pairs had no significant differ-
ences from one another with respect to other known
HSCT outcome predictors33 (Table 1). In previous studies
which investigated the role of HLA-E compatibility in
HSCT outcome, Fürst et al. did not observe any associa-
tion between HLA-E mismatch and HSCT outcome,
while the results of Harkensee et al. suggested a negative
impact of HLA-E incompatibility on survival.20,23 These
two studies, however, were designed on a different basis,
hence the results are not comparable. The cohort of Fürst
et al., apart from its significantly smaller size (n=116), was
heterogeneous in terms of diagnoses, which for reasons
that will be analyzed subsequently, may be of fundamen-
tal importance. The Harkensee et al. study rationale was
performed in an HLA-mismatched setting and its primary
goal was to establish associations between various non-
HLA genetic factors and HSCT outcome for HLA dis-
parate transplant pairs. Previous studies16-19,21,22 reported
lower transplantation related mortality, less severe bacter-
ial infection rates as well as lower relapse and severe
GvHD incidences in patients with the HLA-E*01:03 geno-
type. We could not confirm these associations. In our mul-
tivariate models, where patient HLA-E genotype was a
significant covariate, patient HLA-E*01:03 homozygosity
was, in fact, correlated with inferior outcome. However, it
must be acknowledged that any comparison between
these studies and ours is not applicable, as some of them
included HSCT from related or HLA-E-matched
donors,16,18,22 and cohorts in all of them were not only sig-
nificantly smaller in size but also heterogeneous with
regard to diagnoses.16-19,21,22 
According to our findings, HLA-E mismatch appears to
confer its beneficial effect through dampening of NRM.
On account of this, two very interesting observations are
of note. First, that HLA-E mismatch seems to differentially
impact patients according to their disease stage, and sec-
ondly, that a putatively combined mechanism may
account for the overall beneficial effect, as the lower NRM
rates in advanced disease patients appear to be prevalently
related with lower GvHD rates, whereas in early/interme-
diate disease patients there is better control of infection.
As far as the first observation is concerned, our results
clearly suggest a much stronger impact of HLA-E mis-
match on advanced disease patients’ outcome (Tables 4,
5). In fact, the results within this subgroup of patients
drive the findings in the entire study cohort since they
clearly reach significance, while the effect of HLA-E mis-
match in the larger group of early/intermediate disease
patients, although visible, does not reach statistical signif-
icance. This is most likely due to the different “baseline”
prognostic odds of the two subgroups.34
It is well known that HLA-E is an important modulator
of NK-cytotoxicity, as it constitutes the main ligand to the
CD94/NKG2A/C group of NK receptors.11 According to
the murine model proposed by Olson et al., early post-
transplant NK alloreactivity could be associated with bet-
ter OS rates due to lower GvHD incidence and NRM.35
The fact that CD94/NKG2A/C receptors are the first to
appear on freshly reconstituted NK cells immediately fol-
lowing HSCT, strengthens the assumption that this “HLA-
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Table 4. Univariate analysis of advanced vs. non-advanced patients with respect to human leukocyte antigen (HLA)-E mismatch.
Endpoints Advanced disease patients n=120* Early/intermediate disease patients n=389†
Overall Survival HLA-E-matched HLA-E-mismatched P HLA-E-matched HLA-E-mismatched P
1 year 0.32(0.23-0.46) 0.57(0.43-0.76) 0.005 0.68(0.62-0.74) 0.72(0.65-0.80) 0.071
3 year 0.20(0.12-0.33) 0.54(0.39-0.74) 0.50(0.43-0.57) 0.60(0.52-0.69)
5 year 0.18(0.11-0.31) 0.50(0.35-0.71) 0.45(0.38-0.53) 0.56(0.48-0.65)
Disease free survival
1 year 0.27(0.18-0.40) 0.52(0.38-0.72) 0.002 0.60(0.53-0.67) 0.60(0.52-0.69)
3 year 0.16(0.09-0.28) 0.52(0.38-0.72) 0.43(0.37-0.51) 0.51(0.43-0.60) 0.26
5 year 0.12(0.06-0.24) 0.40(0.25-0.62) 0.39(0.33-0.47) 0.46(0.38-0.56)
Non-relapse mortality
1 year 0.48(0.36-0.59) 0.32(0.17-0.48) 0.038 0.20(0.15-0.26) 0.16(0.11-0.23) 0.083
3 year 0.55(0.42-0.66) 0.32(0.17-0.48) 0.26(0.20-0.32) 0.18(0.12-0.25)
5 year 0.55(0.42-0.66) 0.32(0.17-0.48) 0.29(0.23-0.36) 0.20(0.14-0.27)
Relapse incidence
1 year 0.31(0.20-0.43) 0.24(0.10-0.41) 0.60 0.24(0.18-0.30) 0.25(0.18-0.33) 0.86
3 year 0.33(0.22-0.45) 0.24(0.10-0.41) 0.29(0.23-0.35) 0.30(0.23-0.28)
5 year 0.37(0.25-0.49) 0.35(0.16-0.54) 0.32(0.26-0.39) 0.32(0.24-0.40)
cGvHD incidence
6 months 0.50(0.30-0.67) 0.13(0.03-0.30) 0.009 0.31(0.24-0.39) 0.27(0.19-0.36) 0.60
12 months 0.50(0.30-0.67) 0.13(0.03-0.30) 0.36(0.29-0.44) 0.32(0.23-0.41)
24 months 0.50(0.30-0.67) 0.13(0.03-0.30) 0.37(0.29-0.45) 0.36(0.27-0.46)
*Advanced disease patients, n=120. Omitted observations due to missing data for overall survival=2, disease free survival=1, non-relapse mortality=2, relapse incidence= 14 and
cGvHD incidence=69. †Early/intermediate disease patients, n=389. Omitted observations due to missing data for overall survival=4, disease free survival=3, non-relapse mortali-
ty=4, relapse incidence= 6 and cGvHD incidence=148. Statistical significance is marked in italics. cGvHD: chronic graft-versus-host disease.
E effect”, at least as far as the “dampening” of GvHD is
concerned, could be NK-mediated.36,37
Numerous studies have highlighted the prominent
effect of peptide specificity in peptide/HLA-E (pHLA-E)
complexes as to the affinity and intensity of HLA-E inter-
actions with its corresponding NK receptors, namely the
inhibitory CD94/NKG2A and the activating
CD94/NKG2C.9-10,38-43 The impact of HLA-E polymor-
phism, with respect to the NK “licensing” process, has not
yet been investigated and as such remains elusive. Given
the apparent ability of CD94/NKG2 receptors to discrimi-
nate different pHLA-E constellations through differential
binding affinity, however, it is plausible to assume that
during their “licensing” phase NK cells may be educated
and tuned according to “self” pHLA-E patterns. Moreover,
it has been shown that under abnormal conditions (e.g.,
infection, stress or tumorigenesis) HLA-E molecules are
able to present “unconventional” peptides, generating
pHLA-E complexes that go unnoticed by the dominant
inhibitory CD94/NKG2A receptor, while on certain occa-
sions they instigate activating signals through the
CD94/NKG2C receptor.12 This in turn may lead to exacer-
bated NK activation. According to our hypothesis model,
in an advanced-stage AL setting, aggravated stress condi-
tions, heavier leukemia-cell burden and further alterations
due to advanced leukemogenesis44 may lead to an
enhanced NK-mediated attenuation of T cell
alloreactivity.45 This, in succession, could explain the sig-
nificantly lower GvHD related mortality observed in
advanced disease patients.  
As previously mentioned, cause of death analysis in
advanced and non-advanced disease patients revealed two
potential mechanisms implicated - at a different degree
according to disease stage - in a significant reduction of
NRM rates. The decrease of GvHD-related death in
advanced disease patients, as discussed above, may be
NK-mediated. The reduction of fatal infection-related
death in non-advanced disease patients, on the other
hand, is more likely to be T cell-mediated, as it has been
reported that HLA-E-restricted αβ T cells may play a sig-
nificant role in the control of viral as well as bacterial
infections (CMV, Epstein-Barr virus (EBV), human immun-
odeficiency virus  (HIV), M.tuberculosis, S. typhi etc.).14
Given the role of HLA-E allelic variation in the specificity
of HLA-E bound peptides, the ability of HLA-E to bind
pathogen-derived peptides13 and the importance of pep-
tide specificity in TCR recognition of pHLA-E complex-
es,14 it is plausible to presume that in an HLA-E-mis-
matched context, the chances of pathogen-specific HLA-
E-restricted T cells to encounter the right pHLA-E constel-
lation may be significantly higher due to a theoretically
extended pHLA-E repertoire on account of HLA-E dispar-
ity. In an infection setting, “unconventional” pHLA-E com-
plexes can be presented by both donor antigen presenting
cells (APCs) and patient infected cells, hence pathogen-
specific donor HLA-E-restricted T cells are more likely to
encounter an immune-response-instigating pHLA-E pat-
tern.14,43 These two independent mechanisms probably act
synergistically but to a different degree according to dis-
ease stage. The differences observed in the two subgroups
may be the result of NK interference in the T cell-mediat-
ed infection control potential in advanced disease patients
on the one hand, and the less intense NK activation in
early/intermediate disease patients due to lighter disease
burden on the other. 
Significant limitations of our study are the incomplete-
ness of the data regarding significant clinical parameters,
such as aGvHD, cGvHD, type of infection and CMV
reactivation, which would allow for a much more thor-
ough and precise understanding of the way in which
HLA-E mismatch exerts its beneficial effect on NRM and
OS. Despite these drawbacks, however, the size and
homogeneity of our cohort with respect to diagnosis,
type of donor and HLA compatibility, certainly justify
further investigation with larger confirmatory cohorts
and functional in vitro studies. Considering that AL
patients constitute the majority of all HSC-transplanted
patients, and that even 10/10 HLA-matched unrelated
transplant pairs have about 30-40% chance to be HLA-E
disparate, our data support future integration of HLA-E
compatibility as an additional clinical predictor, which
ought to be considered upon selection of an optimal
donor in an AL setting. Even though our findings, from a
statistical point of view, did not confirm the effect of
HLA-E mismatch in “early/intermediate disease” patients,
we suspect, on account of our hypothesis model, that all
AL patients, albeit to a different degree, could benefit
from HLA-E disparate grafts. Future larger independent
cohort studies, such as that of our ongoing CIBMTR
IB16-01 project with more than 1500 AL patients
enrolled, which may or may not confirm these results,
will undoubtedly show the way.
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Table 5. Multivariate analysis of advanced vs. non-advanced patients with respect to HLA-E mismatch.
Advanced disease patients n=120* Early/intermediate disease patients n=389†
Endpoints HR CI 95% P HR CI 95% P
Overall Survival 0.40 0.22-0.72 0.002 0.75 0.55-1.04 0.088
Disease free survival 0.42 0.25-0.72 0.001 0.85 0.63-1.15 0.29
Non-relapse mortality 0.44 0.20-0.95 0.036 0.72 0.46-1.12 0.14
Relapse incidence 1.10 0.50-2.43 0.81 1.05 0.72-1.55 0.80
cGvHD incidence 0.18 0.05-0.65 0.008 0.86 0.56-1.31 0.48
*Advanced disease patients, n=120. Omitted observations due to missing data for overall survival=2, disease free survival=1, non-relapse mortality=2, relapse incidence= 14 and
cGvHD incidence=69. †Early/intermediate disease patients, n=389. Omitted observations due to missing data for overall survival=4, disease free survival=3, non-relapse mortality=4,
relapse incidence= 6 and cGvHD incidence=148. Hazard ratio (HR) values for survival endpoints (Overall survival and Disease free survival) refer to the risk of death and/or
relapse as measured in the analyses for these endpoints. cGvHD: chronic graft-versus-host disease.
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